Integrated DNA Technologies is expanding its next-generation sequencing portfolio with the addition of the new xGen Inherited Disease and Pan-Cancer Panels.
The first of these new offerings was introduced at a recent American College of Medical Genetics and Genomics event and was designed in collaboration with Emory Genetics Laboratory. It combines the ease of whole exome sequencing with the low cost of panels.
“Integrated DNA Technologies is launching two new xGen next-generation sequencing panels for the detection of inherited diseases and cancer.“
Meanwhile, the Pan-Cancer Panel will be launched at the American Association for Cancer Research annual meeting next week and targets coding regions in 127 significantly mutated genes across 12 tumour types.
The target enrichment technology featured in the xGen products has made next-generation sequencing more accessible by enabling users to focus efforts on specific regions of the genome, proving more cost-effective and reliable than whole genome sequencing.
Ibrahim Jivanjee, product manager for next-generation sequencing at Integrated DNA Technologies, said: "A rapidly advancing area, next-generation sequencing is key to the development of personalised medicine, and these two new panels will aid us in supporting advancements in human health and clinical research."
This comes after the firm introduced its xGen Universal Blocking Oligos at the end of last year.